|1.||Willson, Douglas F: 7 articles (08/2015 - 01/2005)|
|2.||Thomas, Neal J: 6 articles (09/2013 - 01/2005)|
|3.||Egan, Edmund E: 3 articles (08/2015 - 09/2013)|
|4.||Conaway, Mark R: 2 articles (08/2015 - 01/2005)|
|5.||Tamburro, Robert: 2 articles (09/2013 - 09/2013)|
|6.||Pediatric Acute Lung and Sepsis Investigators Network: 2 articles (09/2013 - 09/2013)|
|7.||Conaway, Mark: 2 articles (09/2013 - 09/2013)|
|8.||Truemper, Edward: 2 articles (09/2013 - 09/2013)|
|9.||Traul, Christine: 2 articles (09/2013 - 09/2013)|
|10.||Truwit, Jonathon: 2 articles (09/2013 - 09/2013)|
|1.||Respiratory Insufficiency (Respiratory Failure)
03/01/2005 - "The model was calibrated using outcomes and resource utilization observed in a multiple-centered, prospective, randomized, controlled unblinded trial of Infasurf in pediatric acute hypoxemic respiratory failure. "
01/26/2005 - "A multicenter, randomized, blinded trial of calfactant compared with placebo in 153 infants, children, and adolescents with respiratory failure from ALI conducted from July 2000 to July 2003. "
03/01/2005 - "To determine whether the use of exogenous surfactant (Infasurf) in pediatric acute hypoxemic respiratory failure is cost-effective. "
01/26/2005 - "To determine if endotracheal instillation of calfactant in infants, children, and adolescents with ALI would shorten the course of respiratory failure. "
01/26/2005 - "Calfactant acutely improved oxygenation and significantly decreased mortality in infants, children, and adolescents with ALI although no significant decrease in the course of respiratory failure measured by duration of ventilator therapy, intensive care unit, or hospital stay was observed."
|2.||Adult Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
08/01/2015 - "The Adult Calfactant in Acute Respiratory Distress Syndrome Trial."
09/01/2013 - "Post hoc analysis of daily fluid balance in subjects from the Pediatric Calfactant in Acute Respiratory Distress Syndrome trial. "
09/01/2013 - "The relationship of fluid administration to outcome in the pediatric calfactant in acute respiratory distress syndrome trial."
09/01/2013 - "Pediatric calfactant in acute respiratory distress syndrome trial."
02/01/2007 - "Prone positioning was demonstrated in a recent pediatric trial to have no effect on outcome, while calfactant was found to potentially improve outcomes in pediatric acute respiratory distress syndrome. "
|3.||Acute Lung Injury
09/01/2008 - "All children, defined as immunocompromised, enrolled in a multicenter, masked, randomized, control trial of calfactant for acute lung injury conducted between July 2000 and July 2003. "
09/01/2008 - "Post hoc analysis of calfactant use in immunocompromised children with acute lung injury: Impact and feasibility of further clinical trials."
05/01/2014 - "Calfactant: is there a potential role in acute lung injury?"
09/01/2008 - "To assess the impact of calfactant (a modified natural bovine lung surfactant) in immunocompromised children with acute lung injury and to determine the number of patients required for a definitive clinical trial of calfactant in this population. "
01/01/2007 - "A critical appraisal of a randomized controlled trial: Willson et al: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury (JAMA 2005, 293: 470-476)."
10/01/2010 - "Calfactant therapy is promising and may be considered in children with direct lung injury and ARDS. "
09/01/2013 - "Children 37 weeks postconception to 18 years old with lung injury/acute respiratory distress syndrome due to direct lung injury were randomized to receive up to three doses of 30 mg/cm height of surfactant (calfactant) versus placebo (air) within 48 hours of intubation and initiation of mechanical ventilation. "
09/01/2013 - "Calfactant in Acute Respiratory Distress Syndrome was a masked randomized controlled trial of calfactant surfactant versus placebo in pediatric patients with acute lung injury/acute respiratory distress syndrome due to direct lung injury. "
08/01/2015 - "In view of the positive results of our studies in children along with evidence that surfactant-associated protein B containing pharmaceutical surfactants might be more effective, we designed a multiinstitutional, randomized, controlled, and masked trial of calfactant, a calf lung surfactant, in adults and children with ALI/ARDS due to direct lung injury. "
|5.||Birth Weight (Birth Weights)
12/01/2012 - "We conducted a multicenter randomized, blinded, pilot study to assess the safety and efficacy of late administration of doses of a surfactant protein-B (SP-B)-containing surfactant (calfactant) in combination with prolonged inhaled nitric oxide (iNO) in infants ≤1,000 g birth weight (BW). "
09/01/2011 - "A total of 87 infants, 500 to 1250 g birth weight, who were ventilated at 7 to 10 days received 2 or 3 doses of Infasurf (Calfactant, Forest Pharmaceuticals, St Louis, MO, USA) within a 1-week period. "
|1.||Surface-Active Agents (Surfactants)
|2.||IgA receptor (protein B)
|3.||Nitric Oxide (Nitrogen Monoxide)
|5.||Exosurf (Exosurf Neonatal)
|6.||poractant alfa (Curosurf)
|8.||Technetium (Technetium 99m)
|10.||Proteins (Proteins, Gene)
|1.||Mechanical Ventilators (Ventilator)
|2.||Neonatal Intensive Care
|4.||Artificial Respiration (Mechanical Ventilation)